Highlights from the Week of 27th April 2026 - 4th May 2026

VYUHPHARMA

(FDA, Approval)

AstraZeneca's fixed-dose triple-combination therapy, BREZTRI AEROSPHERE, gains FDA approval for the maintenance treatment of asthma in patients aged 12 and older

(FDA, Approval)

Arvinas' VEPPANU receives FDA approval as the first-ever PROTAC therapy for the treatment of adults with ER+ or HER2- or ESR1 mutated, advanced or metastatic breast cancer

(FDA, Approval)

FDA approves Incyte's JAKAFI XR extended-release tablets to treat adults with intermediate- or high-risk myelofibrosis, polycythemia vera and adults or children who are 12 years and older with GVHD

(FDA, Approval)

Axsome secures approval from the FDA for its AUVELITY, targeting NMDA and sigma-1 receptors to treat dementia due to Alzheimer's disease

(TGA, Approval)

Australia's TGA approves Arrowhead Pharmaceuticals' REDEMPLO, a siRNA adjunct to diet that reduces triglyceride levels for adult patients with familial chylomicronemia syndrome

(FDA, Priority Review)

FDA provides Priority Review acceptance to Johnson & Johnson's sBLA IMAAVY, to treat warm autoimmune hemolytic anemia

(Acquisition)

UCB acquires IMIDomics' Patients Insights Business, with direct access to the most advanced, deeply curated human datasets in immunology, accelerating its precision-driven therapeutic discovery and development

(Collaboration)

Shionogi enters into absorption merger agreement with Torii Pharmaceutical, aiming to strengthen its domestic business and to enhance its ability to deliver medicines

(Collaboration)

Daiichi Sankyo collaborates with MMV to conduct hit-to-lead research on novel antimalarial PfPFN inhibitors for malaria parasites

(Phase 3, Results)

Mundipharma's Phase 3 global ReSPECT trial evaluating REZZAYO demonstrates comparable PK/PD in reducing the incidence of invasive fungal diseases, with favorable benefit/risk profile for immunocompromised patients